On June 2, a refrigerated logistics truck loaded with the first batch of CSPC Innovation’s Enyike® (Generic Name: Ustekinumab Injection) slowly departed from the production site of CSPC Giant Biopharmaceutical Co., Ltd., marking the official launch of commercial sales for CSPC Innovation’s ustekinumab product. This adds another robust product to China’s domestic biopharmaceutical portfolio.
On May 21, 2026, the Marketing Authorization Application for CSPC Innovation’s ustekinumab injection was approved by the National Medical Products Administration (NMPA), indicated for the treatment of plaque psoriasis in adult and pediatric patients.Following the approval of Enyike®, the company’s management at all levels expedited deployment to make the medicine available to patients as early as possible.
Relevant staff systematically carried out work covering production, quality control, marketing and other links. All preparations ahead of the first commercial shipment were finalized within less than two weeks.
For this delivery, CSPC Innovation adopts a combined air and ground transportation scheme for multi-channel distribution. Shipments will arrive successively in Hebei, Beijing, Tianjin, Shandong, Shanxi and Henan within the next 24 hours, and reach all regions nationwide within 48 hours.
Enyike<sup>®</sup> is a fully human monoclonal antibody targeting the shared p40 subunit of IL‑12 and IL‑23. A total of 446 subjects were enrolled in its Phase III clinical trial. Study results demonstrated that at Week 12 of treatment, the PASI 75 response rate of the Enyike®\ (SYSA1902) cohort reached 83.3%, versus 79.3% for the reference innovator product.
The drug exhibits highly comparable efficacy to the originator with a favorable safety profile and no serious adverse reactions observed.In addition, its convenient once‑every‑12‑week dosing regimen substantially improves treatment adherence and medication accessibility for patients. Featuring outstanding quality, proven safety, convenient administration and superior cost‑effectiveness, Enyike<sup>®</sup> is poised to deliver optimized overall clinical benefits to Chinese patients with moderate‑to‑severe plaque psoriasis.